America’s Diner continues its long-standing tradition of saying 'thank you' to all active and retired military personnel Denny's Veterans Day 2025 Denny’s Honors Veterans with Free Original Grand Slam® for Veterans Day Spartanburg, S.C., Oct. 22, 2025 (GLOBE NEWSWIRE) -- This Veterans Day, Denny’s invites active and retired military personnel to America’s Diner to enjoy a FREE Original Grand Slam® from 5 a.m. (store open) to noon local time at participating locations nationwide*. The iconic, guest-favori ...

Q3 2025 REVENUES In challenging market conditions and an uncertain geopolitical environment, Synergie recorded Revenues of €825.0 million in the third quarter of 2025, an increase of +1.8 % year-on-year. In € millionQ3 2025Q3 2024Variation9M 20259M 2024VariationInternational505.1497.4+1.5%<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ...

Third quarter turnover up +31% Q3 2025 turnover increased to 164.7 million euros (+31%), driven by Services Energy Sales: Growth in production +6% (to 1.3 terawatt-hours), driven by improved resource levels and growth in operating capacity. Turnover decrease of -13% (-10% at constant exchange rates), mainly penalised by an unfavourable EUR/BRL exchange rate relative to 2024, a curtailment impact on Brazil production, and a price effect due to the end of short-term contracts at high prices (effects of early ...

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received a prior KRAS(OFF) G12C inhibitor. These results will be highlighted in an oral presentation at the AACR-NCI-EORTC S ...

Accessibility StatementSkip Navigation Faster Fixes, Fewer OutagesA new electric substation is planned to be up and running by December 2026. It will be connected to the existing Sydney Substation by two new half-mile power lines. These additions will bring more electricity to the area, making the system more flexible if a customer's main power line is taken out of service and will help crews restore power more quickly during outages. Construction recently kicked off on new substation and backup power lines ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased WPP plc ("WPP†or the "Company†) (NYSE: WPP) common stock between February 27, 2025 and July 8, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WPP PLC (WPP), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWS. ...

Q3 2025 REVENUES In challenging market conditions and an uncertain geopolitical environment, Synergie recorded Revenues of €825.0 million in the third quarter of 2025, an increase of +1.8 % year-on-year. In € millionQ3 2025Q3 2024Variation9M 20259M 2024VariationInternational505.1497.4+1.5%<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ...

PRESS RELEASE - REGULATED INFORMATION HYBRID SOFTWARE GROUP REPORTS Q3 REVENUE UP 16% AND OPERATING PROFIT UP 200% FROM LAST YEAR Cambridge (UK) 22 October 2025 (18.00 CEST) – Hybrid Software Group PLC (Euronext: HYSG) provides a trading update for the nine months ended 30 September 2025. This information is unaudited. For the quarter ended 30 September 2025: Revenue for the period was €13.42 million (2024: €11.57 million)EBITDA for the period was €3.52 million, or 26% of revenue (2024: €2.01 million, 17% o ...

Abstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed anti-PD-1 and the combination was superior to either agent alone. Additional data will be presented with the poster on Saturday, October 25Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeu ...

Core Viewpoint - ONWARD Medical N.V. is launching a capital increase through a private placement aimed at raising approximately EUR 50 million to support its operations and development initiatives in neurotechnology for spinal cord injuries and movement disabilities [1][2]. Summary by Sections Private Placement Overview - The private placement will involve the issuance of new ordinary shares with a nominal value of EUR 0.12 each, offered to qualified institutional investors [1][3]. - The final number of shares and the issue price will be determined through a bookbuilding process, which is expected to last one business day [4][5]. Use of Proceeds - The net proceeds from the private placement will be allocated as follows: - 40% for product development, clinical studies, and regulatory activities for the ARC-IM System - 30% to expand sales and operations for the ARC-EX System - 20% to support quality and administrative activities - 5% for working capital and general corporate purposes - 5% to cover financing costs, including existing debt obligations [2][6]. Trading and Regulatory Aspects - Trading of ONWARD Medical's shares will be temporarily suspended on Euronext Brussels, Amsterdam, and Paris during the bookbuilding period to facilitate broader investor participation [5][7]. - The new shares are expected to be listed and admitted to trading on October 28, 2025, with payment and delivery occurring on the same day [9]. Company Background - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement and independence in individuals with spinal cord injuries and other movement disabilities [11]. - The company has developed the ARC Therapy and has received multiple Breakthrough Device Designations from the FDA for its products [11].